Chugai Files For Additional Indication Of Ovarian Cancer For Avastin
This article was originally published in PharmAsia News
Chugai Pharmaceuticals announced on Oct. 5 that it has filed for an additional indication for anti-cancer drug Avastin (bevacizumab) for ovarian cancer.
You may also be interested in...
The $250m deal adds A&E Medical’s sternal sutures, cable systems, and rigid fixation systems to Zimmer Biomet’s Dental, Spine & Craniomaxillofacial and Thoracic business.
The Phase III clinical trial showed a noticeable placebo effect compared with OV101.
The company will invest $1.2bn over the next four years to expand and upgrade its manufacturing capacity for pre-fillable syringes and advanced drug delivery systems across seven manufacturing facilities.